Urgency to meet the world's worsening load of COVID-19 cases appeared unflagging Thursday, with four new trials kicking off to evaluate treatments aimed at keeping people from progressing to worsened disease and reports on two new variant-focused efforts yielding signs of preclinical promise.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aft, Alcon, Annovis, Asklepios, Brooklyn Immunotherapeutics, Canbridge, Capricor, Delix, Hikma, Inozyme, Mindset, Mirum, Moderna, Novartis, Park, Repertoire, Selecta, Sirnaomics, Tris, Walvax.
HONG KONG – Researchers at The Chinese University of Hong Kong (CUHK) have developed an artificial intelligence (AI)-based system for the automated, rapid and accurate detection of COVID-19 infections in chest computed tomography (CT) images. The system can provide immediate results, without the need for clinicians to interpret images. It could be potentially used in radiology imaging departments in hospitals.
CMS has posted the draft Medicare inpatient rule for fiscal year 2022, replete with the usual controversies over reassignment of procedures under the Medicare diagnostic grouping system. One bit of good news is that the agency may carry over several expired new technology add-on payments (NTAPs) into the coming fiscal year, a move prompted by the difficulty of collecting claims data from fiscal year 2020 due to the COVID-19 pandemic.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amplyx, Bayer, Biomarin, Cannabics, Dermtech, Essa, Grifols, Homology, Lilly, Mallinckrodt, Neuraly, Okyo, Pfizer, Point, Silence, Soligenix, Triplet, Twist, VBI, Vifor, Vivlion.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advanced Biological Laboratories, Fractyl Laboratories, Johnson & Johnson Vision.
Astrazeneca plc’s saga of its COVID-19 vaccine continued this week with the European Commission (EC) deciding to begin legal action against the Cambridge, U.K.-based company, claiming it has failed to deliver doses in line with its contract.
RSS
